Genmab A/S (GE9.F)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
212.50
0.50 (0.24%)
At close: Jan 14, 2025, 5:16 PM
undefined% (undefined)
Bid | n/a |
Market Cap | 13.50B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | 4.859 |
PE Ratio (ttm) | 43.73 |
Forward PE | n/a |
Analyst | n/a |
Ask | n/a |
Volume | 19 |
Avg. Volume (20D) | 70 |
Open | 215.00 |
Previous Close | 212.00 |
Day's Range | 212.50 - 215.00 |
52-Week Range | 188.00 - 289.10 |
Beta | undefined |
About GE9.F
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosi...
Industry n/a
Sector n/a
IPO Date Oct 23, 2000
Employees 2,635
Stock Exchange XETRA
Ticker Symbol GE9.F
Website https://www.genmab.com